Core Insights - BetterLife Pharma Inc. has completed an IND-enabling cardiac safety study for BETR-001, showing minimal impact on the hERG channel, which is crucial for cardiac function [1][2] - The CEO of BetterLife expressed satisfaction with the hERG safety data, which aligns with previous in vivo cardiac safety telemetry studies and indicates that BETR-001 acts as an antagonist at the 5HT-2B receptor, unlike LSD and other psychedelics [2] - The clean cardiac safety profile of BETR-001 brings the company closer to completing full IND-enabling studies and initiating clinical trials [2] Company Overview - BetterLife Pharma is focused on developing and commercializing BETR-001 and BETR-002 for neuro-psychiatric and neurological disorders [3] - BETR-001 is a non-hallucinogenic LSD derivative that is unregulated and can be self-administered, with a synthesis patent that eliminates regulatory hurdles [4] - BETR-002, based on honokiol, is also in preclinical studies and targets anxiety-related disorders, including benzodiazepine dependency [5]
BetterLife Obtains Favourable Cardiac Safety Data for BETR-001